Solid Tumor, Adult Clinical Trials

47 studies are recruiting for solid tumor, adult in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

   The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Arkansas Medical School, Little Rock, Arkansas

   Locations

   19 in total

   Run by

   NiKang Therapeutics, Inc.

   See if you can join NCT06586957 on ClinicalTrials.gov

2. A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

   This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment opti…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   23 in total

   Run by

   Nested Therapeutics, Inc

   See if you can join NCT06326411 on ClinicalTrials.gov

3. A Study of VET3-TGI in Patients With Solid Tumors

   VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or whe…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   USC/Norris Comprehensive Cancer Center, Los Angeles, California

   Locations

   7 in total

   Run by

   KaliVir Immunotherapeutics

   See if you can join NCT06444815 on ClinicalTrials.gov

4. Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

   This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which n…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   12 in total

   Run by

   Vivace Therapeutics, Inc

   See if you can join NCT04665206 on ClinicalTrials.gov

5. A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

   Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers. The preliminary objective of this study is aimed at selecting PD-1+ and CTLA4+ T cells and other cellular fractions from peripheral bl…

   Stage

   Not phased

   Ages

   5 and older

   Site

   Carolina BioOncology Institute, Huntersville, North Carolina

   Run by

   BioCytics, Inc.

   See if you can join NCT00571389 on ClinicalTrials.gov

6. An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

   Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UT Health, San Antonio, Texas

   Locations

   3 in total

   Run by

   Shenzhen Ionova Life Sciences Co., Ltd.

   See if you can join NCT04443088 on ClinicalTrials.gov

7. A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

   The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center, La Jolla, California

   Locations

   26 in total

   Run by

   Frontier Medicines Corporation

   See if you can join NCT06244771 on ClinicalTrials.gov

8. 64Cu-GRIP B in Patients With Advanced Malignancies

   This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET) imaging can be safe and useful for detecting granzyme B (GrB) in patie…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   Rahul Aggarwal

   See if you can join NCT05888532 on ClinicalTrials.gov

9. Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

   This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study investigators will a…

   Stage

   Phase 1

   Ages

   1 to 40

   Site

   Johns Hopkins Hospital, Baltimore, Maryland

   Locations

   4 in total

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT03465592 on ClinicalTrials.gov

10. A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

    The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be treated effectively w…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    O'Neal Comprehensive Cancer Center at University of Alabama-Birmingham, Birmingham, Alabama

    Locations

    41 in total

    Run by

    Corbus Pharmaceuticals Inc.

    See if you can join NCT06265727 on ClinicalTrials.gov

11. Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

    This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Henry Ford Cancer Institute, Detroit, Michigan

    Locations

    7 in total

    Run by

    Sairopa B.V.

    See if you can join NCT05856981 on ClinicalTrials.gov

12. A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

    The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebuli…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    XCancer Research Network/Dothan Hematology & Oncology, Dothan, Alabama

    Locations

    14 in total

    Run by

    Krystal Biotech, Inc.

    See if you can join NCT06228326 on ClinicalTrials.gov

13. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, cataly…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Arizona Cancer Center, Tucson, Arizona

    Locations

    37 in total

    Run by

    Relay Therapeutics, Inc.

    See if you can join NCT05216432 on ClinicalTrials.gov

14. Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors

    TRE-515 is a first-in-class small molecule inhibitor of deoxycytidine kinase (dCK) that is being developed for oral administration in patients with solid tumors. In cancer cells, rapid and upregulated DNA replication creates high replication stress, as such, cancer cells are more susceptible than n…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCLA, Santa Monica, California

    Locations

    2 in total

    Run by

    Trethera

    See if you can join NCT05055609 on ClinicalTrials.gov

15. A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

    The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Banner MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    10 in total

    Run by

    A2 Biotherapeutics Inc.

    See if you can join NCT06682793 on ClinicalTrials.gov

16. A Beta-only IL-2 ImmunoTherapY Study

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sharp Memorial Hospital, San Diego, California

    Locations

    27 in total

    Run by

    Medicenna Therapeutics, Inc.

    See if you can join NCT05086692 on ClinicalTrials.gov

17. BP1001-A in Patients With Advanced or Recurrent Solid Tumors

    This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is es…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Holy Cross Hospital, Silver Spring, Maryland

    Locations

    4 in total

    Run by

    Bio-Path Holdings, Inc.

    See if you can join NCT04196257 on ClinicalTrials.gov

18. Personalized Models for Cancer Research

    The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate cancer research ranging from disease mechanisms to personalized medicine approaches that will help to realize the promise of precision medicine for oncology.

    Stage

    Not phased

    Ages

    18 and older

    Site

    New York Stem Cell Foundation Research Institute, New York, New York

    Run by

    New York Stem Cell Foundation Research Institute

    See if you can join NCT06350539 on ClinicalTrials.gov

19. A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

    This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Angeles Clinic and Research Institute, Los Angeles, California

    Locations

    13 in total

    Run by

    GV20 Therapeutics

    See if you can join NCT05669430 on ClinicalTrials.gov

20. A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention

    Genetic factors are a significant determinant of the likelihood of developing various types of cancers. Identification of germline risk can have important implications for both patients and their families. Although estimates vary, pathogenic germline variants can be seen in ~3-17.5% of unselected p…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Enloe Regional Cancer Center, Chico, California

    Locations

    2 in total

    Run by

    University of California, Davis

    See if you can join NCT06436157 on ClinicalTrials.gov

21. Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

    This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determ…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth Research Institute, Scottsdale, Arizona

    Locations

    3 in total

    Run by

    BioEclipse Therapeutics

    See if you can join NCT04282044 on ClinicalTrials.gov

22. Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer

    The purpose of the randomized control trial is to estimate the effect of an oncology clinical nurse specialist-led early intervention multidisciplinary approach to palliative and survivorship care within two previously identified and validated patient groups having metastatic solid tumor malignancy…

    Stage

    Not phased

    Ages

    21 and older

    Site

    Good Samaritan University Hospital, West Islip, New York

    Run by

    Good Samaritan Hospital Medical Center, New York

    See if you can join NCT05947695 on ClinicalTrials.gov